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Abstract
Introduction: Recent studies have reported a risk reduction in the progression of benign breast disease to breast
carcinoma through COX-2 pathways.
Case presentation: We present a case of severe epithelial hyperplasia in a 47-year-old woman with increased
breast density submitted to scintimammography by the proliferation-imaging tracer Technetium-99m-labelled
pentavalent dimercaptosuccinic acid, before and after an oral ibuprofen treatment for 4 weeks. The radiotracer
uptake after ibuprofen intake was significantly reduced, both visually and by semi-quantitative analysis, based on a
calculation of lesion-to-background ratios.
Conclusion: In proliferating breast lesions, scintigraphically displayed reduction in Technetium-99m-labelled
pentavalent dimercaptosuccinic acid uptake may indicate inhibition by ibuprofen in the pathway of malignant
epithelial cell transformation.
Introduction
Several epidemiological and laboratory studies suggest
that non-steroidal anti-inflammatory drugs (NSAIDs)
may have chemo-preventive effects in breast cancer,
owing to their activity against cyclo-oxygenase-2
(COX-2), the rate-limiting enzyme in the prostaglandin
cascade [1]. Recent studies have suggested that inflam-
mation through COX-2 pathways may play a role in
the progression of benign breast disease to breast car-
cinoma, and that aspirin may reduce this risk in
women with similar lesions [2]. Significant reductions
in the risk of malignant transformation have been
reported with selective COX-2 inhibitors, as well as
with over-the-counter non-steroidal anti-inflammatory
drugs, including ibuprofen and naproxen [1].
Another important related consideration is the postu-
lated association between benign proliferating breast
disease, mammographic density, and subsequent malig-
nant transformation [2-4]. Technetium-99m-labelled
pentavalent dimercaptosuccinic acid (99mTc-(V)DMSA)
is a tumor-seeking radiotracer. Its relationship to focal
adhesion kinase (FAK) activation and cellular prolifer-
ating activity has been described in previous reports
not only for invasive but also for pre-invasive and
benign proliferating breast lesions [5-8]. This case
report was undertaken to investigate whether a reduced
rate of cellular proliferation, mediated by ibuprofen as
described in previous retrospective studies, could be
visualized by alterations in the patient’s 99mTc-(V)
DMSA uptake ratio.
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Case presentation
A 47-year-old Caucasian woman of Greek national ori-
gin was referred to our department with a mammogram
showing increased breast density with multiple dispersed
nodular opacities, linear opacities, periareolar fibrosis,
and microcalcifications in the lower outer quadrant of
her right breast. Histology of an open biopsy specimen
(Figure 1) showed foci of severe epithelial hyperplasia,
areas of calcification, and apocrine metaplasia. Scinti-
mammography with 99mTc-(V)DMSA was performed
2 days before the scheduled biopsy and then 7 months
later. Within 4 weeks before the follow-up study, our
patient took oral ibuprofen (400 mg daily) for persistent
musculoskeletal back pain.
After intravenous administration of 925MBq of the
tracer, early and late planar (lateral prone and anterior
supine) images were acquired at 10 minute and 60 min-
ute after injection. Breast 99mTc-(V)DMSA uptake in the
early and late images was evaluated visually. Quantita-
tive comparisons between the 10 minute and 60 minute
scans and between the baseline study before biopsy and
after the course of ibuprofen were performed by draw-
ing regions of interest (ROIs) over the breast sites of
greatest tracer uptake and over the normal breast par-
enchyma. The lesion-to-background (L/B) ratios were
then calculated and compared between the same corre-
sponding breast areas in the two scintigraphic studies.
A pattern of diffuse widespread tracer uptake corre-
sponding to pre-invasive breast pathology (epithelial
hyperplasia and in situ carcinoma, according to our pre-
vious reports [5,8]), was also observed in this case
(Figure 2). This diffuse 99mTc-(V)DMSA distribution
almost entirely occupied our patient’s right breast par-
enchyma and was evident in the images both before
(Figures 2A and 2B) and after her ibuprofen treatment
(Figures 2C and 2D). There was a gradual increase in
the relative uptake of the tracer on the delayed images,
compared with the early ones. However, after her ibu-
profen treatment, diffuse tracer uptake was clearly
diminished in both the early (Figure 2C) and late (Figure
2D) images. The L/B ratios in the 10 minute and
60 minute images were 1.562 and 2.719 (Figure 2A and
2B, respectively) in the baseline study versus 1.229 and
1.993 (Figure 2C and 2D, respectively) at follow-up
examination. Based on our recent study, women without
epithelial hyperplasia or with usual ductal breast hyper-
plasia without increased cellular proliferation rate (Ki-67
≤ 3%) show 99mTc-(V)DMSA L/B60 min ratios in the
range of 1.07 to 1.31 (mean = 1.15) and 0.77 to 1.62
(mean = 1.2), respectively (5).
Discussion
Our key finding is that a short period of ibuprofen treat-
ment resulted in a 27% reduction in the uptake of
99mTc-(V)DMSA in a case of proliferative benign epithe-
lial breast hyperplasia. Other recent studies have shown
that COX-2 inhibitors may reduce the risk of breast
cancer [1]. Specifically, a retrospective study of almost
1000 women showed that a selective COX-2 inhibitor,
celecoxib 200 mg/day for at least two years, reduced the
risk of breast cancer by 83%, while rofecoxib 25 mg/day
reduced the risk by 64% [1]. The non-selective COX
inhibitors aspirin and ibuprofen and/or naproxen gave a
reduced odds ratio (0.49 and 0.37, respectively, with
95% confidence intervals) for the incidence of breast
Figure 1 Extensive severe ductal epithelial hyperplasia of usual
type and apocrine metaplasia (Hematoxylin and Eosin staining,
×100).
Figure 2 Images of (A) early pre-ibuprofen, (B) late pre-
ibuprofen (C) early post-ibuprofen, and (D) late post-
ibuprofen treatment of 99 mTc-(V)DMSA distribution. After
ibuprofen treatment, the diffuse tracer uptake is clearly diminished
in both early (C) and late imaging (D).
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cancer compared with non-use. Moreover, the odds
ratio for breast cancer by dose and frequency was
0.28 for ibuprofen 200 mg more than 3 times weekly.
In this context, other investigators have suggested that
inflammation mediated through COX-2 pathways may
play a role in the progression of benign breast disease
to carcinoma, and that aspirin may reduce such risk in
women with benign breast disease [2].
99mTc-(V)DMSA is a tumor-seeking tracer whose cel-
lular uptake is linked to FAK activation and cell prolif-
eration, which is a precocious stage of malignant
transformation [6,7,9]. Compared with invasive lesions,
the exact mechanism of 99mTc-(V)DMSA accumulation
in benign proliferating diseases and in some non-prolif-
erating diseases with higher L/B ratios is not yet clear
[5,7]. Given that benign proliferating diseases generally
have lower proliferation rate than invasive cancers, this
raises the suspicion that 99mTc-(V)DMSA reflects an
earlier cell activation status of phosphorylated FAK in
the process of increasing the rate of cell proliferation
[5,6,8]. Hence, in our case, the reduction in diffuse
99mTc-(V)DMSA uptake after a relatively short period
(4 weeks) of ibuprofen treatment may indicate a “switch
off” mechanism on activated FAK, rather than a slowing
down of the proliferation rate. Although we have pro-
vided no biopsy confirmation after treatment, ibuprofen
was the only treatment that our patient took between
her scintimammographic studies. The biokinetic charac-
teristics of 99mTc-(V)DMSA support our suggestion that
the observed reduction in its uptake was attributable to
ibuprofen-induced cyclo-oxygenase COX inhibition.
Conclusion
Our research so far has shown that diffuse tracer uptake
during 99mTc-(V)DMSA scintimammography can be
considered indicative of an underlying proliferative
hyperplastic or in situ pathology. This report focuses on
a patient with severe breast epithelial hyperplasia
enrolled in a current prospective study. In another
recent report on hyperplastic lesions [10], we studied
the imaging properties and biokinetic characteristics of
99mTc-(V)DMSA in relation to mammographic density.
As long as these lesions can be visualized, it would be of
great clinical interest if we could estimate the effective-
ness of various chemopreventive agents by quantifying
their effect on 99mTc-(V)DMSA uptake.
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